[212Pb]Pb-MP0712

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Large Cell Neuroendocrine Carcinoma

Conditions

Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC

Trial Timeline

Jan 1, 2026 → Sep 1, 2032

NCT ID

NCT07278479

About [212Pb]Pb-MP0712

[212Pb]Pb-MP0712 is a phase 1/2 stage product being developed by Molecular Partners for Large Cell Neuroendocrine Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07278479. Target conditions include Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC).

What happened to similar drugs?

1 of 20 similar drugs in Large Cell Neuroendocrine Carcinoma were approved

Approved (1) Terminated (2) Active (17)

✅RAD001 + Paclitaxel + CarboplatinNovartisApproved

🔄Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + GemcitabineAbbViePhase 3

🔄Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3

🔄acalabrutinib + placebo + Prednisone + Rituximab + Cyclophosphamide + Vincristine + DoxorubicinAstraZenecaPhase 3

🔄AZD0486 + R-mini-CHOPAstraZenecaPhase 3

🔄R-miniCHOP + Acalabrutinib + R-miniCHOPAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07278479	Phase 1/2	Recruiting	Jan 1, 2026	Sep 1, 2032	Large Cell Neuroendocrine Carcinoma

Competing Products

20 competing products in Large Cell Neuroendocrine Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)	Eli Lilly	Phase 2	35
rituximab	Celltrion	Phase 1	21
YM155	Astellas Pharma	Phase 2	27
enzastaurin + gemcitabine + rituximab + oxaliplatin	Eli Lilly	Phase 2	35
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6	Johnson & Johnson	Phase 2	31
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine	Johnson & Johnson	Phase 2	35
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	42
Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine	AbbVie	Phase 3	47
ABBV-525	AbbVie	Phase 1	36
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab	AbbVie	Phase 1/2	36
Copanlisib + Venetoclax	AbbVie	Phase 1/2	36
Epcoritamab + Investigator's Choice Chemotherapy	AbbVie	Phase 3	44
Epcoritamab + Lenalidomide	AbbVie	Phase 2	39
Venetoclax + Selinexor	AbbVie	Phase 1	29
Epcoritamab	AbbVie	Phase 1	36
Loncastuximab Tesirine and Epcoritamab	AbbVie	Phase 2	42
Epcoritamab + Epcoritamab, tafasitamab and lenalidomide	AbbVie	Phase 2	42
Epcoritamab + Investigator's Choice Chemotherapy	AbbVie	Phase 3	44
bendamustine + navitoclax + rituximab	AbbVie	Phase 2	27
Epcoritamab	AbbVie	Phase 2	39